From: Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: Prominent expression of P-cadherin
IBC
Non-IBC
p-value
n(%)
Basal cases (ER-,ERBB2-)
18/19(95%)
35/51(69%)
0.05
ERBB2-overexpressing cases
9/13(69%)
32/47(68%)
NS
Luminal cases (ER+, PR+)
14/17(82%)
84/197(43%)
<0.01